Phase 1 N=32 Single-Dose Study of MT203
Healthy Volunteers
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) — 3; 3; 1; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Bosutinib in Adult Patients With Recurrent Glioblastoma
Glioblastoma
Primary: Progression-Free Survival — 7.71 weeks
Phase 1 N=105 Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
Parkinson Disease
Primary: Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1) — 182; 794; 1540; 176 ng/mL
Phase 2 N=62 The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain
Neck Pain
Primary: 2 Week Change in Pain Score on a Numeric Rating Scale — 6.39; 20.37; 6.45 units on a scale — p=0.10
Phase 1 N=175 Rehabilitation of Patients After THR - Based on Patients´Selfrated Health
Total Hip Replacement
Primary: Change in Physical Dimensions in Health Status of Elderly Patients From 4 Weeks Pre Operatively to 9 Months Post Operatively After THR. Health Status is Measured by the…
Phase 4 N=20 Metabolic Abnormalities in HIV-infected Persons
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
Phase 4 N=29 Lumbar Stenosis Outcomes Research (LUSTOR)
Lumbar Spinal Stenosis
Primary: Time to First Symptoms of Moderate Pain — 2.52; 3.06 minutes
Phase 2 N=1,395 A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
Urinary Bladder, Overactive
Primary: Base Study/Part 1: Change From Baseline in Average Daily Micturitions at Week 8 — -1.16; -1.62; -1.61; -1.80 Micturitions — p=0.056
Phase 1 N=131 A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Malignant Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts — 0; 0; 1; 0 participants
Phase 2 N=92 A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
Adenomatous Polyposis Coli
Primary: Change in Duodenal Polyp Burden From Baseline to 6 Months — -8.5; 8.0 mm — p=<0.001
N/A N=88 The Use of Skills Training to Augment Compensated Work Therapy (CWT)/VI for Veterans With SMI
Mental Illness · Schizophrenia
Primary: Employment Status — 26.2; 24.83 Hours worked per week
N/A N=10 Circadian Brown Adipose Tissue Metabolism
Healthy
Primary: Change in Maximum Standardized Update Value (SUVmax) in Brown Adipose Tissue FDG Uptake in the Neck or Upper Chest on Evening and Imaging Compared to Morning Imaging
N/A N=30 Plasma of Argon Cleaning on Implant Abutments: 5-year Results of a Randomized Clinical Trial
Endosseous Dental Implant Failure · Alveolar Bone Loss
Primary: Success Rate of the Implants and Prostheses (Participants). — 100; 100 percentage of participants — p=<0.05
N/A N=441 Choosing Healthy Options in College Environments and Settings
Obesity
Primary: Change in Body Mass Index (BMI) — 26.2; 26.0 kg/m2 — p=0.707
N/A N=13 Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
Type 2 Diabetes · Oxidative Stress
Primary: Fasting Urine F2 Alpha Isoprostane Levels — -0.089 ng/ml